Proteon Therapeutics (NASDAQ:PRTO) released its quarterly earnings results on Wednesday, March 14th. The biopharmaceutical company reported ($0.31) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.45) by $0.14, Yahoo Finance reports.
PRTO stock traded down $0.05 on Friday, hitting $2.45. The company had a trading volume of 25,109 shares, compared to its average volume of 42,611. Proteon Therapeutics has a 12-month low of $1.10 and a 12-month high of $2.85. The stock has a market capitalization of $44.19, a P/E ratio of -1.15 and a beta of 1.51.
PRTO has been the subject of several analyst reports. Zacks Investment Research raised shares of Proteon Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Thursday, January 4th. Robert W. Baird set a $3.00 price target on shares of Proteon Therapeutics and gave the company a “hold” rating in a research report on Wednesday, March 14th. Finally, HC Wainwright set a $2.00 price target on shares of Proteon Therapeutics and gave the company a “hold” rating in a research report on Friday, March 16th. Four analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus target price of $3.38.
ILLEGAL ACTIVITY WARNING: This article was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this article on another domain, it was stolen and reposted in violation of United States & international copyright and trademark law. The original version of this article can be read at https://www.dispatchtribunal.com/2018/04/07/proteon-therapeutics-prto-announces-quarterly-earnings-results.html.
Proteon Therapeutics Company Profile
Proteon Therapeutics, Inc, a late-stage biopharmaceutical company, focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular diseases. It develops vonapanitase, a recombinant human elastase, which is in Phase III clinical trial for patients with chronic kidney disease undergoing surgical creation of a radiocephalic fistula for hemodialysis; has completed a Phase I/II clinical trial in patients undergoing placement of an arteriovenous graft; and is in Phase I clinical trial for the treatment of symptomatic peripheral artery disease.
Receive News & Ratings for Proteon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.